Cargando…
Capter 11 Filtering in Drug Discovery
This chapter discusses the concept of filtering in drug discovery. Multiple filters may be incorporated into a definition of drug-likeness and this leads to tradeoffs among compound properties in compounds intended for screening. The optimization of compound properties may require some type of multipa...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128845/ https://www.ncbi.nlm.nih.gov/pubmed/32288696 http://dx.doi.org/10.1016/S1574-1400(05)01011-X |
_version_ | 1783516654782644224 |
---|---|
author | Lipinski, Christopher A. |
author_facet | Lipinski, Christopher A. |
author_sort | Lipinski, Christopher A. |
collection | PubMed |
description | This chapter discusses the concept of filtering in drug discovery. Multiple filters may be incorporated into a definition of drug-likeness and this leads to tradeoffs among compound properties in compounds intended for screening. The optimization of compound properties may require some type of multiparameter optimization scheme in library design. Fingerprint algorithms can be used to guide diversity. Filters also need to be employed in the chemistry synthesis planning process so that good quality compounds are made. Differences in property ranges between oral and injectable drugs are summarized in the chapter. Oral drugs are lower in MWT and have fewer H-bond donors, acceptors, and rotatable bonds. A scheme for separating central nervous system (CNS)- from non-CNS-active drugs in the WDI allowed the discovery of simple parameters relating to passive blood brain barrier (BBB) permeability and the prediction of p-glycoprotein (PGP) affinity. The PGP transporter is a major barrier to the entry of compounds to the CNS. Appropriately determined PGP efflux ratios can be used as a measure of compound affinity to PGP. |
format | Online Article Text |
id | pubmed-7128845 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71288452020-04-08 Capter 11 Filtering in Drug Discovery Lipinski, Christopher A. Annu Rep Comput Chem Article This chapter discusses the concept of filtering in drug discovery. Multiple filters may be incorporated into a definition of drug-likeness and this leads to tradeoffs among compound properties in compounds intended for screening. The optimization of compound properties may require some type of multiparameter optimization scheme in library design. Fingerprint algorithms can be used to guide diversity. Filters also need to be employed in the chemistry synthesis planning process so that good quality compounds are made. Differences in property ranges between oral and injectable drugs are summarized in the chapter. Oral drugs are lower in MWT and have fewer H-bond donors, acceptors, and rotatable bonds. A scheme for separating central nervous system (CNS)- from non-CNS-active drugs in the WDI allowed the discovery of simple parameters relating to passive blood brain barrier (BBB) permeability and the prediction of p-glycoprotein (PGP) affinity. The PGP transporter is a major barrier to the entry of compounds to the CNS. Appropriately determined PGP efflux ratios can be used as a measure of compound affinity to PGP. Elsevier B.V. 2005 2005-10-05 /pmc/articles/PMC7128845/ /pubmed/32288696 http://dx.doi.org/10.1016/S1574-1400(05)01011-X Text en Copyright © 2005 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Lipinski, Christopher A. Capter 11 Filtering in Drug Discovery |
title | Capter 11 Filtering in Drug Discovery |
title_full | Capter 11 Filtering in Drug Discovery |
title_fullStr | Capter 11 Filtering in Drug Discovery |
title_full_unstemmed | Capter 11 Filtering in Drug Discovery |
title_short | Capter 11 Filtering in Drug Discovery |
title_sort | capter 11 filtering in drug discovery |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128845/ https://www.ncbi.nlm.nih.gov/pubmed/32288696 http://dx.doi.org/10.1016/S1574-1400(05)01011-X |
work_keys_str_mv | AT lipinskichristophera capter11filteringindrugdiscovery |